GoAI
Get started
ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$75.35

−$1.97 · -2.55%

Aug 21, 4:00 PM ET

ANIP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

95

Deep Value

Momentum

46

Neutral

Sentiment

49

Mixed

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Nikhil Lalwani
Listed since
May 5, 2000
Employees
970

Market position

Day range

Current $75.35

52-week range

Current $75.35

Open
$77.75
Previous close
$77.32
Volume
379.16K
1.1× average
Average volume
343.55K
Average daily volume
Market cap
1.71B USD
Beta
0.46
Market reference 1
50-day average
$80.3136
-6.18% below average
200-day average
$80.0754
-5.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.62B USD
P/E (TTM)
15.6×
P/B (TTM)
2.67×
P/S (TTM)
1.75×
EV / EBITDA
7.83×
Earnings yield
4.95%
Free cash flow yield
9.53%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
65.23%
Operating margin
15.35%
Net margin
10.82%
Return on equity
14.49%
Return on assets
5.44%
Return on invested capital
5.63%

Financial health

Debt / equity
0.55×
Current ratio
2.71×
Altman Z-score
2.64
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends71%38%5%-28%Gross margin, FY2021: 53.45%Gross margin, FY2022: 56.13%Gross margin, FY2023: 62.71%Gross margin, FY2024: 59.27%Gross margin, FY2025: 51.01%Operating margin, FY2021: -18.41%Operating margin, FY2022: -11.15%Operating margin, FY2023: 9.65%Operating margin, FY2024: 0.10%Operating margin, FY2025: 9.20%Net margin, FY2021: -19.71%Net margin, FY2022: -15.14%Net margin, FY2023: 3.86%Net margin, FY2024: -3.01%Net margin, FY2025: 8.87%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.45%. Gross margin FY2022 56.13%. Gross margin FY2023 62.71%. Gross margin FY2024 59.27%. Gross margin FY2025 51.01%. Operating margin FY2021 -18.41%. Operating margin FY2022 -11.15%. Operating margin FY2023 9.65%. Operating margin FY2024 0.10%. Operating margin FY2025 9.20%. Net margin FY2021 -19.71%. Net margin FY2022 -15.14%. Net margin FY2023 3.86%. Net margin FY2024 -3.01%. Net margin FY2025 8.87%.

Income trends

Revenue

883.37M USD+43.78%

Operating income

81.23M USD+13809.25%

Net income

78.34M USD+96.86M USD
Income trends across reported periods976.49M USD603.99M USD231.48M USD−141.02M USDRevenue, FY2021: 216.14M USDRevenue, FY2022: 316.39M USDRevenue, FY2023: 486.82M USDRevenue, FY2024: 614.38M USDRevenue, FY2025: 883.37M USDOperating income, FY2021: −39.79M USDOperating income, FY2022: −35.28M USDOperating income, FY2023: 46.97M USDOperating income, FY2024: 584K USDOperating income, FY2025: 81.23M USDNet income, FY2021: −42.6M USDNet income, FY2022: −47.9M USDNet income, FY2023: 18.78M USDNet income, FY2024: −18.52M USDNet income, FY2025: 78.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 216.14M USD. Revenue FY2022 316.39M USD. Revenue FY2023 486.82M USD. Revenue FY2024 614.38M USD. Revenue FY2025 883.37M USD. Operating income FY2021 −39.79M USD. Operating income FY2022 −35.28M USD. Operating income FY2023 46.97M USD. Operating income FY2024 584K USD. Operating income FY2025 81.23M USD. Net income FY2021 −42.6M USD. Net income FY2022 −47.9M USD. Net income FY2023 18.78M USD. Net income FY2024 −18.52M USD. Net income FY2025 78.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue883.37M USD614.38M USD486.82M USD316.39M USD216.14M USD
Cost of goods sold432.73M USD250.21M USD181.51M USD138.79M USD100.61M USD
Gross profit450.64M USD364.17M USD305.3M USD177.6M USD115.53M USD
Research and development51.66M USD44.58M USD34.29M USD22.32M USD11.37M USD
Selling, general, and administrative317.75M USD249.64M USD161.7M USD124.04M USD84.29M USD
Operating expenses369.41M USD363.58M USD258.33M USD212.88M USD155.32M USD
Interest expense20.06M USD17.6M USD26.94M USD28.05M USD11.92M USD
Depreciation and amortization91.42M USD67.73M USD59.79M USD59.65M USD47.25M USD
Operating income81.23M USD584K USD46.97M USD−35.28M USD−39.79M USD
Net income78.34M USD−18.52M USD18.78M USD−47.9M USD−42.6M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+23.09%
11 comparable reports
Latest EPS result
2.21
Estimate 2.04 · Beat by 8.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.422.011.61.19Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 1.63, estimate 1.41, surprise +15.60%, Beat. Q2 2025, reported May 9, 2025: actual 1.7, estimate 1.37, surprise +24.09%, Beat. Q3 2025, reported Aug 8, 2025: actual 1.8, estimate 1.38, surprise +30.43%, Beat. Q4 2025, reported Nov 7, 2025: actual 2.04, estimate 1.74, surprise +17.24%, Beat. Q1 2026, reported Feb 27, 2026: actual 2.33, estimate 1.99, surprise +17.09%, Beat. Q2 2026, reported May 8, 2026: actual 2.05, estimate 1.28, surprise +60.16%, Beat. Q3 2026, reported Aug 7, 2026: actual 2.21, estimate 2.04, surprise +8.33%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate 2.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates291.26M247.1M202.93M158.76MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 190.57M USD, estimate 169.96M USD, surprise +12.13%, Beat. Q2 2025, reported May 9, 2025: actual 197.12M USD, estimate 188.73M USD, surprise +4.44%, Beat. Q3 2025, reported Aug 8, 2025: actual 211.37M USD, estimate 208.81M USD, surprise +1.23%, Beat. Q4 2025, reported Nov 7, 2025: actual 227.81M USD, estimate 232.25M USD, surprise -1.91%, Miss. Q1 2026, reported Feb 27, 2026: actual 247.06M USD, estimate 231.09M USD, surprise +6.91%, Beat. Q2 2026, reported May 8, 2026: actual 237.46M USD, estimate 207.63M USD, surprise +14.37%, Beat. Q3 2026, reported Aug 7, 2026: actual 266.04M USD, estimate 260.13M USD, surprise +2.27%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate 280.06M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$104.5

38.69% upside
Past 12 months12-month forecastHigh $119Average $104.5Low $90.00

Rating distribution

10 ratings
Strong buy00%
Buy660%
Hold440%
Sell00%
Strong sell00%

ANIP news

defenseworld.net

Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty…

Read source
zacks.com

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

Read source
zacks.com

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

Read source
zacks.com

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

Read source
seekingalpha.com

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jul 18, 2013

1:6

Stock split

Effective Jun 4, 2012

1:6

Stock split

Effective Jun 3, 2002

1:10

ANIP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ANIP

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
84.38M
Weight
0.07%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
48.7M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
48.12M
Weight
0.15%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
40.15M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
16.59M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
14.67M
Weight
0.10%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
13.16M
Weight
0.08%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
12.88M
Weight
0.15%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9+0.61%

Continue in GoAI

Research ANIP

research.disclaimer